Oramed Pharmaceuticals Inc. Adds Another Accomplished Member to Its Scientific Board
22 February 2007 - 12:38AM
PR Newswire (US)
JERUSALEM, Feb. 21 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
(OTC:ORMPOTC:Frankfurt:OTC:OJU) (BULLETIN BOARD: ORMP, Frankfurt:
OJU) further enhances its Scientific board of directors with the
addition of Prof. Ele Ferrannini. Having published over 350
original papers and 50 book chapters he is amongst the "highly
cited scientists." (ISIhighlycited.com). One of many great honors
achieved for Prof. Ferrannini includes being elected a past
President to the EASD, European Association for the Study of
Diabetes. The Association is based on individual membership and
embraces scientists, physicians, laboratory workers, nurses and
students from all over the world who are interested in diabetes and
related subjects for Europe, such that the ADA, American Diabetes
Association does in America. Prof. Ferrannini has worked with
various institutions including the Department of Internal Medicine,
University of Pisa School of Medicine, and CNR (National Research
Council) Institute of Clinical Physiology, Pisa, Italy; Diabetes
Division, Department of Medicine, University of Texas Health
Science Center at San Antonio, Texas, USA. He has also had
extensive training focused on microbiology, immunology,
endocrinology, and specializing in diabetes studies. Prof.
Ferrannini has received a Certificate of the Educational Council
for Foreign Medical Graduates from the University of Bologna, and
with cum laude honors completed a subspecialty in Diabetes and
Metabolic Diseases from the University of Torino. CEO, Nadav Kidron
stated, "We are very pleased with this new addition to the Oramed
family, because he brings not only a strong mind, but accolades
from the commercial pharmaceutical world, as well as his many other
honorable accomplishments in the diabetes realm." Oramed
Pharmaceuticals looks forward to what Prof. Ferrannini can bring to
the table with the myriad of international diabetes council
memberships, strong resume, and accolades in medicine. About Oramed
Pharmaceuticals, Inc: Oramed Pharmaceuticals' is an Israeli based
company focused on the development of oral delivery solutions based
on proprietary technology. Diabetes is one of the most rapidly
growing diseases in the world and is one that requires constant and
often unpleasant monitoring and drug therapy regimen. Oramed is
currently developing an orally soft gel insulin capsule for the
treatment of diabetes. The Company is also pursuing the development
of oral delivery solutions for other drugs and vaccines. For more
information on Oramed Pharmaceuticals please visit our website:
http://www.oramedpharma.com/ Investor Relations Contact: Oramed
Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252
http://www.oramedpharma.com/ DATASOURCE: Oramed Pharmaceuticals
Inc. CONTACT: Vinisha Agnihotri of Oramed Pharmaceuticals, Inc.,
+1-646-467-2252, Web site: http://www.oramedpharma.com/
Copyright